Hahn N - Search Results

1

Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer.

Flanagan J, Gray PK, Hahn N, Hayes J, Myers LJ, Carney-Doebbeling C, Sweeney CJ. Flanagan J, et al. Among authors: hahn n. Ann Oncol. 2011 Apr;22(4):801-807. doi: 10.1093/annonc/mdq443. Epub 2010 Sep 29. Ann Oncol. 2011. PMID: 20880998 Free article.

2

Germ cell tumors: an update of recent data and review of active protocols in stage I and metastatic disease.

Hahn NM, Sweeney CJ. Hahn NM, et al. Urol Oncol. 2005 Jul-Aug;23(4):293-302. doi: 10.1016/j.urolonc.2005.05.008. Urol Oncol. 2005. PMID: 16018947 Review.

3

Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis.

Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, Johnson CS, Scott-Horton TJ, Li L, McLeod HL, Sweeney CJ. Hahn NM, et al. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6094-9. doi: 10.1158/1078-0432.CCR-06-1188. Clin Cancer Res. 2006. PMID: 17062685 Clinical Trial.

4

Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer.

Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Berry WR, Kadmon D. Sonpavde G, et al. Among authors: hahn n. Cancer. 2007 Dec 15;110(12):2628-39. doi: 10.1002/cncr.23085. Cancer. 2007. PMID: 17941029 Free article. Review.

5

Novel agents for muscle-invasive and advanced urothelial cancer.

Sonpavde G, Ross R, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Lerner SP, Sternberg CN. Sonpavde G, et al. Among authors: hahn n. BJU Int. 2008 Apr;101(8):937-43. doi: 10.1111/j.1464-410X.2007.07326.x. Epub 2007 Nov 13. BJU Int. 2008. PMID: 18005203 Review.

6

Constitutional polymorphisms of prostate cancer: prognostic and diagnostic implications.

Hahn NM, Kelley MR, Klaunig JE, Koch MO, Li L, Sweeney CJ. Hahn NM, et al. Future Oncol. 2007 Dec;3(6):665-82. doi: 10.2217/14796694.3.6.665. Future Oncol. 2007. PMID: 18041919 Review.

7

Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate.

Hahn NM, Reckova M, Cheng L, Baldridge LA, Cummings OW, Sweeney CJ. Hahn NM, et al. J Clin Oncol. 2009 Jan 20;27(3):460-3. doi: 10.1200/JCO.2008.19.9380. Epub 2008 Dec 8. J Clin Oncol. 2009. PMID: 19064958 No abstract available.

8

A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67.

Hahn NM, Zon RT, Yu M, Ademuyiwa FO, Jones T, Dugan W, Whalen C, Shanmugam R, Skaar T, Sweeney CJ. Hahn NM, et al. Ann Oncol. 2009 Dec;20(12):1971-6. doi: 10.1093/annonc/mdp244. Epub 2009 Jul 15. Ann Oncol. 2009. PMID: 19605506 Free article. Clinical Trial.

9

Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; Denosumab HALT Prostate Cancer Study Group. Smith MR, et al. N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003. Epub 2009 Aug 11. N Engl J Med. 2009. PMID: 19671656 Free PMC article. Clinical Trial.

10

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).

Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G. Harrison MR, et al. Invest New Drugs. 2011 Dec;29(6):1465-74. doi: 10.1007/s10637-010-9455-x. Epub 2010 May 25. Invest New Drugs. 2011. PMID: 20499131 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

399 results

Search Page